EGF Receptor mRNA in Ovarian Cancer
Author Information
Author(s): JMS Bartlett, SP Langdon, BJB Simpson, M Stewart, D Katsaros, P Sismondi, S Love, WN Scott, ARW Williams, AM Lessells, KG Macleod, JF Smyth, WR Miller
Primary Institution: Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospital, Edinburgh
Hypothesis
The expression of EGF receptor mRNA is associated with poor prognosis in primary ovarian cancer.
Conclusion
The presence of EGF receptor mRNA is linked to reduced survival in patients with malignant ovarian tumors.
Supporting Evidence
- 70% of malignant tumors expressed EGF receptor mRNA.
- Patients with EGF receptor mRNA positive tumors had significantly reduced survival.
- EGF receptor mRNA expression was significantly associated with serous histology.
Takeaway
This study found that a specific marker in ovarian cancer cells, called EGF receptor mRNA, can help predict how well patients might do after treatment.
Methodology
The study used reverse transcriptase-polymerase chain reaction (RT-PCR) to analyze mRNA expression in ovarian tumor samples.
Limitations
The study's findings may not apply to all types of ovarian tumors, as it primarily focused on malignant cases.
Participant Demographics
The study included 97 patients with histologically confirmed primary ovarian tumors, comprising 76 malignant, 6 borderline, and 15 benign tumors.
Statistical Information
P-Value
0.0015 for EGF receptor and TGF-a association; 0.030 for EGF receptor and survival
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website